News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Affymax, Inc. (AFFY) and Takeda Global Research & Development Center, Inc. Report Phase 2 Analyses of Hematide(TM)/peginesatide in Hemodialysis Patients



4/15/2010 8:33:33 AM

ORLANDO, Fla.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease (CKD). The data provide hypotheses for further investigation of this agent in anemia management in this patient population. The findings were presented in three separate posters at the National Kidney Foundation (NKF) Annual Meeting being held in Orlando, Florida.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES